Abstract
Several classes of compounds that have no intrinsic activity on aminergic systems nonetheless enhance the potency of aminergic receptor ligands three-fold or more while significantly increasing their duration of activity, preventing tachyphylaxis and reversing fade. Enhancer compounds include ascorbic acid, ethylenediaminetetraacetic acid, corticosteroids, opioid peptides, opiates and opiate antagonists. This paper provides the first review of aminergic enhancement, demonstrating that all enhancers have a common, inobvious molecular motif and work through a common mechanism that is manifested by three common characteristics. First, aminergic enhancers bind directly to the amines they enhance, suggesting that the common structural motif is reflected in common binding targets. Second, one common target is the first extracellular loop of aminergic receptors. Third, at least some enhancers are antiphosphodiesterases. These observations suggest that aminergic enhancers act on the extracellular surface of aminergic receptors to keep the receptor in its high affinity state, trapping the ligand inside the receptor. Enhancer binding produces allosteric modifications of the receptor structure that interfere with phosphorylation of the receptor, thereby inhibiting down-regulation of the receptor. The mechanism explains how enhancers potentiate aminergic activity and increase duration of activity and makes testable predictions about additional compounds that should act as aminergic enhancers.
Keywords: aldosterone, allosteric, allostery, antiphosphodiesterase, ascorbic acid, corticosteroid, dopamine, down-regulation, EDTA, enhancement, enhances, epinephrine, GPCR, histamine, increased potency, molecular complementarity, morphine, naloxone, naltrexone, norepinephrine, opiate, opioid, phosphodiesterase inhibitors, potentiates, potentiation, serotonin, supersensitivity, vitamin C.
Current Medicinal Chemistry
Title:A Common Molecular Motif Characterizes Extracellular Allosteric Enhancers of GPCR Aminergic Receptors and Suggests Enhancer Mechanism of Action
Volume: 21 Issue: 32
Author(s): Robert Root-Bernstein and Patrick F. Dillon
Affiliation:
Keywords: aldosterone, allosteric, allostery, antiphosphodiesterase, ascorbic acid, corticosteroid, dopamine, down-regulation, EDTA, enhancement, enhances, epinephrine, GPCR, histamine, increased potency, molecular complementarity, morphine, naloxone, naltrexone, norepinephrine, opiate, opioid, phosphodiesterase inhibitors, potentiates, potentiation, serotonin, supersensitivity, vitamin C.
Abstract: Several classes of compounds that have no intrinsic activity on aminergic systems nonetheless enhance the potency of aminergic receptor ligands three-fold or more while significantly increasing their duration of activity, preventing tachyphylaxis and reversing fade. Enhancer compounds include ascorbic acid, ethylenediaminetetraacetic acid, corticosteroids, opioid peptides, opiates and opiate antagonists. This paper provides the first review of aminergic enhancement, demonstrating that all enhancers have a common, inobvious molecular motif and work through a common mechanism that is manifested by three common characteristics. First, aminergic enhancers bind directly to the amines they enhance, suggesting that the common structural motif is reflected in common binding targets. Second, one common target is the first extracellular loop of aminergic receptors. Third, at least some enhancers are antiphosphodiesterases. These observations suggest that aminergic enhancers act on the extracellular surface of aminergic receptors to keep the receptor in its high affinity state, trapping the ligand inside the receptor. Enhancer binding produces allosteric modifications of the receptor structure that interfere with phosphorylation of the receptor, thereby inhibiting down-regulation of the receptor. The mechanism explains how enhancers potentiate aminergic activity and increase duration of activity and makes testable predictions about additional compounds that should act as aminergic enhancers.
Export Options
About this article
Cite this article as:
Root-Bernstein Robert and Dillon F. Patrick, A Common Molecular Motif Characterizes Extracellular Allosteric Enhancers of GPCR Aminergic Receptors and Suggests Enhancer Mechanism of Action, Current Medicinal Chemistry 2014; 21 (32) . https://dx.doi.org/10.2174/0929867321666140826120604
DOI https://dx.doi.org/10.2174/0929867321666140826120604 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
Current advances in inherited cardiomyopathy
Describe in detail all novel advances in multimodality imaging related to inherited cardiomyopathy diagnosis and prognosis. Shed light to deeper phenotypic characterization. Acknowledge recent advances in genetics, genomics and precision medicineread more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Anabolics in Osteoporosis: The Emerging Therapeutic Tool
Current Molecular Medicine Calcium Sensitizers in Cardiac Surgery: Who, When, How and Why?
Current Vascular Pharmacology CD95 Signaling in Cancer Treatment
Current Pharmaceutical Design Attenuating Muscle Wasting: Cell and Gene Therapy Approaches
Current Genomics PDE-5 Inhibitors: Clinical Points
Current Drug Targets Subject Index To Volume 6
Current Gene Therapy PI3K/Akt/JNK/c-Jun Signaling Pathway is a Mediator for Arsenite- Induced Cyclin D1 Expression and Cell Growth in Human Bronchial Epithelial Cells
Current Cancer Drug Targets Dry Age-Related Macular Degeneration: Recent Progress of Therapeutic approaches
Current Molecular Pharmacology Remediation of Cellular Hypoxic Damage by Pharmacological Agents
Current Pharmaceutical Design Subclinical Hypothyroidism and Heart Failure Risk in Older People
Endocrine, Metabolic & Immune Disorders - Drug Targets The Use of Statins in Respiratory Diseases
Current Respiratory Medicine Reviews AMPK as a New Attractive Therapeutic Target for Disease Prevention: The Role of Dietary Compounds AMPK and Disease Prevention
Current Drug Targets Current and Experimental Antibody-Based Therapeutics: Insights, Breakthroughs, Setbacks and Future Directions
Current Molecular Medicine Cardiac Protection via Metabolic Modulation: An Emerging Role for Incretin-Based Therapies?
Cardiovascular & Hematological Agents in Medicinal Chemistry Asymptomatic Lone Atrial Fibrillation - How can we Detect the Arrhythmia?
Current Pharmaceutical Design Improving Pediatric Survival from Resuscitation Events: The Role and Organization of Hospital-based Rapid Response Systems and Code Teams
Current Pediatric Reviews IP6 (Inositol Hexaphosphate) as a Signaling Molecule
Current Signal Transduction Therapy Helicase Domain Containing Proteins in Human Disorders
Current Genomics Inhibition of Platelet Glycoprotein Ib and Its Antithrombotic Potential
Current Pharmaceutical Design Clinical Approaches Toward Tumor Angiogenesis: Past, Present and Future
Current Pharmaceutical Design